What Is It?
BPC-157 (GEPPPGKPADDAGLV) is a 15-amino-acid synthetic peptide from human gastric juice. First studied by Sikiric et al. (Zagreb) in 1993. Named 'body protection compound' for its GI mucosal protective effects.
How It Works
Primary mechanism: VEGFR2-Akt-eNOS pathway. BPC-157 upregulates VEGF receptor 2 on endothelial cells, making them more responsive to the body's own growth signals. Result: angiogenesis (new blood vessels) at injury sites.
Independently confirmed: Src-Caveolin-1-eNOS pathway (Hsieh et al., Taiwan, 2020). Disrupts Cav-1/eNOS inhibitory complex, directly promoting nitric oxide production.
BPC-157 upregulates VEGF receptors, not VEGF itself. It amplifies natural repair signaling, not introducing external growth signals.
The Evidence
544+ studies, mostly preclinical. Consistent positive results in: tendon healing (12+), muscle repair (10+), GI protection (50+), bone healing (8+), nerve regeneration (6+), vascular protection (15+).
The majority of BPC-157 research comes from Dr. Predrag Sikiric's group at the University of Zagreb[1]. Well-conducted studies, but lack of broad independent replication is a significant limitation.
Human Data
Only 3 pilot studies exist: knee pain, interstitial cystitis, and PK/safety. No Phase II or Phase III trials. Short plasma half-life (<30 min). Efficacy in humans is unproven by regulatory standards.
Safety
Angiogenesis raises theoretical cancer concerns. No chronic toxicity data. Not FDA-approved. WADA-banned since 2022. Quality of research-grade products varies widely.
Bottom Line
Strongest preclinical evidence of any unapproved therapeutic peptide. Well-characterized mechanism. But 'strong preclinical' ≠ 'proven in humans.' Large-scale clinical trials are needed.